R&D Trends

LEO Pharma, Japan Tobacco ink license agreement for JTE-052

Wednesday, November 5, 2014 12:47 PM

LEO Pharma and Japan Tobacco (JT) have entered into a license agreement, under which LEO Pharma will obtain exclusive rights to further develop, register and market JT’s experimental JAK inhibitor, JTE-052, for topical use in dermatological indications worldwide, excluding Japan where JT retains rights.

More... »

Dana-Farber Cancer Institute, Astellas form research collaboration

Wednesday, November 5, 2014 12:45 PM

Dana-Farber Cancer Institute and Astellas Pharma have inked a three-year R&D collaboration for small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.

More... »


AstraZeneca, Pharmacyclics, Janssen partner

Wednesday, November 5, 2014 12:37 PM

AstraZenecaPharmacyclics and Janssen R&D have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with imbruvica (ibrutinib), an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech. The study will assess the combination as a treatment for patients with hematologic cancers including diffuse large B-cell lymphoma and follicular lymphoma, which are investigational uses for both compounds.

More... »

ALS Association triples spending on research thanks to ice bucket donations

Monday, November 3, 2014 02:44 PM

Thanks to the summer’s Ice Bucket Challenge donations, the ALS Association will be tripling the amount of money it spends on amyotrophic lateral sclerosis (ALS) research. The funds also will support the association’s Certified Treatment Centers of Excellence, which provide evidence-based, multi-disciplinary ALS care and services in a supportive atmosphere with an emphasis on hope and quality of life.

More... »

Cleveland Clinic unveils Top 10 Medical Innovations for 2015

Monday, November 3, 2014 02:41 PM

Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education, has announced its 9th annual list of Top 10 Medical Innovations likely to have major impact on improving patient care in 2015. The list of up-and-coming technologies and drug therapies was selected by a panel of 110 Cleveland Clinic physicians and scientists. The Top 10 Medical Innovations for 2015 are:

More... »

Novo Nordisk invests $126M in new Denmark diabetes research labs

Monday, November 3, 2014 02:38 PM

Novo Nordisk has invested approximately $126 million in new laboratories at the company's R&D campus in Måløv, Denmark. Construction has started, and the new laboratory facility is expected to be ready in early 2016.

More... »

Impax to reorganize R&D, cut 49 jobs

Monday, November 3, 2014 02:32 PM

Impax Laboratories, a Hayward, Calif.-headquartered, technology-based specialty pharmaceutical company, is cutting about a quarter of its R&D work force—42 of a total of 49 job cuts—as part of an R&D reorganization and prioritization of project portfolios within the generic and brand businesses.

More... »

Five foundations to participate in Cavendish Global Health Impact Forum

Friday, October 31, 2014 02:18 PM

Cavendish Global has selected five foundations to participate in the Cavendish Global Health Impact Forum taking place Nov. 10-13 at Oxford University in the U.K. The selected organizations and the participating representatives include:

More... »

Profectus BioSciences receives $9.5M Department of Defense funding for Ebola

Friday, October 31, 2014 02:16 PM

The Department of Defense (DoD), through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program (MCS-JVAP), has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine. Profectus BioSciences is a Baltimore, Md.-based clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases.

More... »

Cancer Innovation Coalition calls for reinvigorated U.S. cancer innovation

Friday, October 31, 2014 02:10 PM

The Cancer Innovation Coalition (CIC) has gone to Capitol Hill to call for early legislative and regulatory action in 2015 that will reinvigorate cancer innovation in the U.S.

More... »

Link to survey



Browse by:


December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs